Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,865
  • Shares Outstanding, K 22,376
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,430 K
  • EBIT $ -28 M
  • EBITDA $ -38 M
  • 60-Month Beta 1.61
  • Price/Sales 2.62
  • Price/Cash Flow N/A
  • Price/Book 0.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.45
  • Most Recent Earnings $-0.80 on 08/12/25
  • Next Earnings Date 05/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 321.40% (-91.86%)
  • Historical Volatility 70.72%
  • IV Percentile 70%
  • IV Rank 30.12%
  • IV High 930.28% on 12/09/25
  • IV Low 58.96% on 01/20/26
  • Expected Move (DTE 25) 0.4250 (59.94%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 22
  • Volume Avg (30-Day) 127
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 9,995
  • Open Int (30-Day) 9,361
  • Expected Range 0.2840 to 1.1340

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +66,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6711 +5.65%
on 02/20/26
0.9450 -24.97%
on 02/12/26
-0.1019 (-12.57%)
since 01/20/26
3-Month
0.6300 +12.54%
on 12/24/25
1.5399 -53.96%
on 11/26/25
-0.2810 (-28.38%)
since 11/20/25
52-Week
0.6300 +12.54%
on 12/24/25
2.4800 -71.41%
on 07/03/25
-1.1410 (-61.68%)
since 02/20/25

Most Recent Stories

More News
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

Third international distribution agreement further advances global access strategy with major markets in Europe

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025

CTXR : 0.7090 (+2.60%)
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

LYMPHIR now available nationwide

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7090 (+2.60%)
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7090 (+2.60%)

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.7754
2nd Resistance Point 0.7469
1st Resistance Point 0.7280
Last Price 0.7090
1st Support Level 0.6806
2nd Support Level 0.6521
3rd Support Level 0.6332

See More

52-Week High 2.4800
Fibonacci 61.8% 1.7733
Fibonacci 50% 1.5550
Fibonacci 38.2% 1.3367
Last Price 0.7090
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar